Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline. In January 2010, the Company completed the acquisition of Symphony Dynamo, Inc. (SDI) from Symphony Dynamo Holdings LLC. Pursuant to the acquisition SDI became a wholly owned subsidiary of the Company.

MiddleBrook Pharmaceuticals was founded in 1999 and is headquartered in Germantown, Maryland. MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its product portfolio includes MOXATAG tablets for the treatment of pharyngitis and tonsillitis; and KEFLEX capsules for the treatment of skin and skin structure infections and upper respiratory tract infections. MiddleBrook Pharmaceuticals sells its products through specialty pharmaceutical distributors and wholesalers to physicians, hospitals, and pharmacies.

AVI BioPharma, Inc. was founded in 1980 and is based in Corvallis, Oregon. AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The company's products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junín viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charley's Fund, Inc.; and the United States Department of Defense.

Merial Limited company makes a variety of drugs and vaccines that treat and prevent disease in pets, livestock, and wildlife. Used by veterinarians, farmers, and pet owners in some 150 countries, Merial company's products include Ivomec, an anti-parasitic for livestock; Frontline flea and tick treatments for cats and dogs; heartworm prevention drug Heartgard; and rabies vaccine Raboral. Merial focuses its R&D on combating parasites, viral and bacterial invaders, and pain, as well as treating chronic conditions of household pets. Merial company is owned by Sanofi-Aventis.

Astellas Pharma was born after Japanese pharmaceutical firms Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical Company merged in 2005, creating one of the largest pharmaceutical companies in Japan. Main products include gastritis treatment Gaster, hypertension therapy Micardis, urology treatment Vesicare, organ transplant immunosuppressant Prograf, and cholesterol drug Lipitor (sold in Japan via an agreement with Pfizer). Astellas' products (including those under development) include cardiovascular, central nervous system, oncology, diabetes, infectious disease, inflammation/immunology, gastroenterology, and urology therapies.

Nuvo Research Inc. primarily focuses on the research and development of drug products that are delivered to and through the skin in Canada. It develops drugs based on two technology platforms, transdermal drug delivery and immune system regulation. The company’s lead products include Pennsaid, a topical non-steroidal anti-inflammatory drug, which is used to treat the pain and symptoms of osteoarthritis of the knee; and Pennsaid Plus, a pre clinical stage product used for applications in various therapeutic areas. Nuvo Research Inc. markets its Pennsaid products in Canada and the Caribbean, as well as in European countries, such as Greece, Italy, and the United Kingdom. Its products also comprise Oxoferin, a topical wound healing agent; and WF10, a chlorite-based, immunomodulating drug, which is in the Phase II clinical trial used for the treatment of inoperable pancreatic cancer. It markets its Oxoferin drug in Europe, Asia, and South America under the Oxoferin and Oxovasin trade names.

Since its inception in 1982, AIM International, Inc. has made and marketed food concentrates and nutritional supplements through direct sales and through "members" who sell and distribute in a multilevel marketing arrangement. On the company's 25th anniversary, CEO Dennis Itami added a personal-care line to the product mix. The company's roster also includes a line of supplements for athletes. AIM International (dba The AIM Companies) has offices in Australia, Canada, New Zealand, South Africa, and the UK. Lead products include AIM BarleyLife and AIMega.

Pacira Pharmaceuticals, Inc. company develops sustained-release therapies based on DepoFoam, an injectable drug delivery technology that allows both immediate and sustained release. Its two marketable products are DepoCyt for treating cancer-related neoplastic meningitis and DepoDur for the treatment of post-operative pain. Pacira's lead candidate is EXPAREL, an injectable local anesthetic. The company has two manufacturing facilities that make its Depo products. Once the injectables subsidiary of drug-delivery company SkyePharma PLC, Pacira was bought out in 2007 by an investor group led by MPM Capital, OrbiMed, HBM Bioventures, and Sanderling Ventures.

Ricerca Biosciences LLC company provides one stop shopping of pharmacology and toxicology, medicinal chemistry, drug substance synthesis, and preclinical and clinical development for small to medium pharmaceutical companies looking to bring drugs to market. The contract research organization (CRO) also offers regulatory filing and report writing services. Ricerca Biosciences provides expanded services through partnerships with companies such as Bicoll Group, Latitude Pharmaceuticals, and Xcelience Formulation Development.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.